Business
Teleflex Announces Updated Clinical Study Data Presented at the European Association of Urology (EAU) Congress
WAYNE, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that new findings from the CLEAR study were presented at the 40th Annual European Association of Urology (EAU) Congress in Madrid, which took place March 21-24, 2025. Among the results, the study showed better early patient satisfaction and sexual function with the UroLift™ System (PUL) compared to Rezūm™ Water Vapor Therapy (WVTT).1 CLEAR is the fi
About this update from Teleflex Incorporated
[{"type":"image","alt":"Teleflex Incorporated","displaySize":"","headline":null,"caption":"Teleflex Incorporated","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":125,"url":"https://media.zenfs.com/en/globenewswire.com/b2d67c9a50caa1f1cddeda86b58ff1b8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/hWX2O.eEUBx79Dv.M4CvaQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3NTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b2d67c9a50caa1f1cddeda86b58ff1b8","width":300,"height":125}},"lazy":false},{"type":"text","content":"WAYNE, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that new findings from the CLEAR study were presented at the 40th Annual European Association of Urology (EAU) Congress in Madrid, which took place March 21-24, 2025. Among the results, the study showed better early patient satisfaction and sexual function with the UroLift™ System (PUL) compared to Rezūm™ Water Vapor Therapy (WVTT).1","length":484,"tagName":"p"},{"type":"text","content":"CLEAR is the first head-to-head randomized controlled trial (RCT) comparing early patient outcomes following treatment with UroLift™ PUL and Rezūm™ WVTT, two minimally invasive treatments for the symptoms of benign prostatic hyperplasia (BPH).1 The study provides critical insights into patient experience, safety, and efficacy, helping physicians and patients make informed treatment decisions.","length":395,"tagName":"p"},{"type":"text","content":"“Comparative clinical trials play a crucial role in guiding treatment decisions for benign prostatic hyperplasia by providing clear, evidence-based insights into safety, efficacy, and patient experience,” said Dr. Matt Ashley, Associate Medical Director at Teleflex. “Understanding how these therapies perform not only in clinical settings but also in real-world patient recovery is essential. At Teleflex, we are committed to advancing research that supports the UroLift™ procedure as a trusted, patient-preferred option for BPH symptom treatment.”","length":549,"tagName":"p"},{"type":"text","content":"Key Study Findings1:","length":20,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"The primary endpoint of the study was catheter-independence between days three and seven post-procedure, measuring how quickly patien...